Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Nowotwór prostaty potwierdzony badaniem histologicznym lub cytologicznym
- •Rak prostaty ze zmianami wykrywalnym specjalnym testem obrazowym (PSMA PET/CT)
- •Niski poziom testosteronu we krwi (poniżej 50 ng/dL)
- •Wcześniejsze leczenie co najmniej dwoma rodzajami chemioterapii lub hormonoterapii
- •Postęp choroby po leczeniu radioaktywnym Lu-177 PSMA
- •Co najmniej jedna widoczna zmiana przerzutowa w badaniach obrazowych z ostatnich 28 dni
- •Prawidłowa funkcja nerek (zgodnie z wymogami badania)
✗ Disqualifies
- •Udzielanie się w innym badaniu klinicznym w ciągu ostatnich 28 dni
- •Wcześniejsze leczenie radioaktywnym aktynem-225
- •Przerzuty do mózgu powodujące objawy lub wymagające sterydów
- •Ostre lub przewlekłe problemy z nerkami
- •Poważne suchość ust
- •Nieregulowane nadciśnienie lub zaburzenia serca w ostatnich 6 miesiącach
- •Inne nowotwory lub historia nowotworów w ostatnich 2 latach (poza drobnoustrojami skóry)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 100 Years
- Last updated (source)
- September 22, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (93)
Honor Health Research Institute
Scottsdale, United States
VA Greater LA Healthcare System
Los Angeles, United States
VA Palo Alto Health Care System
Palo Alto, United States
Stanford University Medical Center
Palo Alto, United States
Sansum Clinic
Santa Barbara, United States
Saint Johns Cancer Institute
Santa Monica, United States
Rocky Mountain Cancer Centers
Denver, United States
Hartford Hospital
Hartford, United States
Baptist Health South
Miami, United States
AdventHealth
Orlando, United States
University Cancer and Blood Center LLC
Athens, United States
Emory University
Atlanta, United States
University of Chicago
Chicago, United States
Indiana University
Indianapolis, United States
University of Kansas Hospital
Kansas City, United States
East Jefferson Hospital
Metairie, United States
Dana Farber Cancer Institute
Boston, United States
Beth Israel Deaconess Medical Center
Boston, United States
WA Uni School Of Med
St Louis, United States
Nebraska Cancer Specialists
Omaha, United States
New Jersey Urology LLC
Voorhees Township, United States
Mount Sinai Hosp Med School
New York, United States
Associated Med Professionals of NY
Syracuse, United States
Montefiore Medical Center
The Bronx, United States
Central Ohio Urology Group
Gahanna, United States
Oregon Urology Institute
Springfield, United States
Fox Chase Cancer Center
Philadelphia, United States
Carolina Urologic Research Center
Myrtle Beach, United States
Texas Oncology
Dallas, United States
Urology San Antonio
San Antonio, United States
Utah Intermountain Medical Center
Murray, United States
Virginia Cancer Specialists
Fairfax, United States
Onco Hemato Asso of SW Virginia
Roanoke, United States
Fred Hutchinson Cancer Research Center
Seattle, United States
Medical College Of Wisconsin
Milwaukee, United States
Novartis Investigative Site
Darlinghurst, Australia
Novartis Investigative Site
Herston, Australia
Novartis Investigative Site
Melbourne, Australia
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
Fuzhou, China
Novartis Investigative Site
Wuhan, China
Novartis Investigative Site
Wuhan, China
Novartis Investigative Site
Nanjing, China
Novartis Investigative Site
Nanjing, China
Novartis Investigative Site
Shenyang, China
Novartis Investigative Site
Xian, China
Novartis Investigative Site
Xian, China
Novartis Investigative Site
Chengdu, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Guangzhou, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Beersheba, Israel
Novartis Investigative Site
Haifa, Israel
Novartis Investigative Site
Jerusalem, Israel
Novartis Investigative Site
Petah Tikva, Israel
Novartis Investigative Site
Ramat Gan, Israel
Novartis Investigative Site
Tel Aviv, Israel
Novartis Investigative Site
Kashiwa, Japan
Novartis Investigative Site
Sapporo, Japan
Novartis Investigative Site
Kobe, Japan
Novartis Investigative Site
Yokohama, Japan
Novartis Investigative Site
Chiba, Japan
Novartis Investigative Site
Fukuoka, Japan
Novartis Investigative Site
Fukuoka, Japan
Novartis Investigative Site
Fukuoka, Japan
Novartis Investigative Site
Fukushima, Japan
Novartis Investigative Site
Ishikawa, Japan
Novartis Investigative Site
Kyoto, Japan
Novartis Investigative Site
Putrajaya, Malaysia
Novartis Investigative Site
Petaling Jaya, Malaysia
Novartis Investigative Site
Petaling Jaya, Malaysia
Novartis Investigative Site
Mexico City, Mexico
Novartis Investigative Site
Huxquilucan, Mexico
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Basel, Switzerland
Novartis Investigative Site
Bellinzona, Switzerland
Novartis Investigative Site
Bern, Switzerland
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Taoyuan, Taiwan
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.